Oncolytic Virotherapy for High-Grade Glioma and Current Evidence and Factors to Consider for Incorporation into Clinical Practice

Brain tumor incidence is on the rise, and glioblastoma comprises majority of primary tumors. Despite maximal safe resection adjuvant chemoradiation, median survival for high-grade glioma remains poor. For this reason, it important to develop incorporate new treatment strategies. Oncolytic virotherapy has emerged as a viable therapeutic entity fill gap. Preclinical research shown oncolytic be robust effective option brain tumors, clinical trials both adult pediatric are underway. The unique protected environment nervous system, in part due blood–brain barrier, prevents traditional systemic therapies from achieving adequate penetration. tumors also heterogenous nature their diverse molecular profiles, further complicating efforts. viruses may serve gap given amenability genetic modification ability target epitopes. In addition, direct inoculation virus agent bed following surgical absolves risk side effects ensures delivery. As transitions bench bedside, discuss factors make transition more seamless. article, we describe current evidence pertains well consider its incorporation into neurosurgical workflow.